Home > Focus Areas > Multiple Myeloma Connect > Post
  • Saved

5h
Anti-CD38 monoclonal antibody-based frontline therapy in transplant-ineligible myeloma: extending benefit to renally impaired patients

The incorporation of anti-CD38 monoclonal antibody therapy into frontline treatment for transplant-ineligible multiple myeloma has transformed outcomes. The phase 3 MAIA trial established the anti-CD38 monoclonal antibody plus lenalidomide-dexamethasone (DRd) triplet as a standard of care, demonstrating superior progression-free survival versus lenalidomide-dexamethasone alone with sustained benefit at extended follow-up. However, patients with severe renal impairment at diagnosis — a high-risk subgroup with significant early morbidity — were historically excluded from pivotal trial populations, creating a clinically meaningful evidence gap.

Emerging real-world data indicate that frontline DRd is feasible and clinically meaningful in transplant-ineligible newly diagnosed myeloma patients with severely impaired renal function (eGFR ≤30 mL/min/1.73 m²). Retrospective series report overall hematologic response rates exceeding 80%, with complete renal responses in approximately 40% of patients — correlating with deeper hematologic responses and significantly prolonged progression-free survival. These findings challenge historical reluctance to deploy full-intensity anti-CD38-based immunotherapy in renally compromised patients and suggest that achieving deep hematologic remission may itself represent the most effective renoprotective strategy. Anti-CD38 monoclonal antibodies do not require dose adjustment for renal impairment, further supporting their use in this population. The evidence shifts the clinical calculus toward earlier, more aggressive treatment rather than sequential watchful adaptation in renally impaired patients.

How do you approach frontline treatment selection in transplant-ineligible newly diagnosed myeloma patients with severe renal impairment, and what parameters guide your decision to initiate anti-CD38-based combination therapy?

What role do depth of hematologic response and early renal recovery play in your prognostic assessment and maintenance planning, and how do you monitor both parameters concurrently in this population?

  • 5h
    For pts with myeloma and renal failure, plasmapheresis may not help reverse the kidney injury. there is evidence that early use of anti CD38 combinations may do so.
    I use anti CD 38 based combinations as much as possible.
    the depth of response and MRD status do predict outcome. I follow the paraproteins and ClonoSeq assays every 3-6 mos if possible
  • 3d
    In transplant-ineligible patients with severe renal impairment, I favor early, aggressive initiation of anti-CD38–based combination therapy, particularly when renal dysfunction is newly diagnosed or suspected to be due to light-chain cast nephropathy, to rapidly reduce the plasma-cell burden and reverse renal injury. Proteasome inhibitors can be safely administered in CKD, while IMiDs such as lenalidomide can also be used with appropriate renal dose adjustment and close hemogram monitoring. I monitor hematologic response with M-protein and free light chains alongside creatinine/eGFR, proteinuria, and other markers of renal recovery, as rapid and deep hematologic response with early renal improvement is an important favorable prognostic indicator.
  • 3d
    In transplant-ineligible patients with severe renal impairment, I favor early, aggressive initiation of anti-CD38–based combination therapy, particularly when renal dysfunction is newly diagnosed or suspected to be due to light-chain cast nephropathy, to rapidly reduce the plasma-cell burden and reverse renal injury. Proteasome inhibitors can be safely administered in CKD, while IMiDs such as lenalidomide can also be used with appropriate renal dose adjustment and close hemogram monitoring. I monitor hematologic response with M-protein and free light chains alongside creatinine/eGFR, proteinuria, and other markers of renal recovery, as rapid and deep hematologic response with early renal improvement is an important favorable prognostic indicator.
  • 3d
    Renal impairment is not a contraindication for anti-CD38 monoclonal antibodies, even on hemodialysis. Proteasome inhibitors can be safely administered in CKD. IMiDs, with dose modification of lenalidomide (and close monitoring of hemogram) can also be safely administered. Patients with new onset renal failure, especially if from light chain cast nephropathy, need to be treated aggressively at diagnosis with the hope of reversing the renal insufficiency.
  • 3d
    frontline treatment prioritizes rapid reduction of nephrotoxic free light chains using a proteasome-inhibitor and anti-CD38 monoclonal antibody backbone (e.g., daratumumab- bortezomib-cyclophosphamide-dexamethasone), with aggressive renal supportive care and strict dose adjustments for any renally cleared components

    In light-chain (AL) amyloidosis, a deep hematologic response stops the supply of toxic light chains. This drop allows early renal recovery to predict a lower risk of end-stage renal disease. Together, they guide maintenance decisions, indicating when to continue therapy or observe
  • 1mo
    We have often used CyborD in this population. Glad to see a study showing benefit to anti CD 38 therapy and suspect this will become a standard of care.. I suspect CyborD + anti CD 38 with also be a SOC. The anti -CD 38 itself is not difficult to give in these patients and it is the other agents that tend to affect or be affect by renal function

Show More Comments